SYBX (Synlogic Corp) מחיר לרווח עתידי

Synlogic, Inc. (SYBX) has effectively ceased operations due to asset liquidation. The company's forward P/E ratio helps track this decline, where the 0.00 metric indicates the status of the current valuation. Previously, the business sought to capture metabolic therapy niches through Synthetic Biotics. Currently, the primary drivers are the monetization of intellectual property, technology licensing, and potential merger deals.

Amidst the transformation of the metabolic therapy market and the focus of Synlogic, Inc. (SYBX) on IP licensing, the business's forward P/E multiple allows for a real-time assessment of asset value relative to expected earnings. This metric is calculated as the ratio of the current market price to the consensus earnings forecast, helping investors avoid overpaying for the asset and determine the company's fair value dynamically.